Section Arrow
Quote
HCM.NASDAQ
- HUTCHMED (China) Limited
Quotes are at least 15-min delayed:2025/09/14 07:43 EDT
Regular Hours
Last
 17.93
+1.56 (+9.53%)
Day High 
18.3 
Prev. Close
16.37 
1-M High
16.57 
Volume 
92.78K 
Bid
17.51
Ask
18.05
Day Low
17.65 
Open
17.65 
1-M Low
14.69 
Market Cap 
2.81B 
Currency USD 
P/E 6.18 
%Yield -- 
10-SMA 15.55 
20-SMA 15.75 
50-SMA 16.43 
52-W High 21.5 
52-W Low 11.505 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
2.65/0.15
Enterprise Value
2.88B
Balance Sheet
Book Value Per Share
7.15
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
227.98M
Operating Revenue Per Share
4.41
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TLRYTilray Brands1.12+0.06+5.66%-- 
IXHLIncannex Healthcare0.5475+0.0175+3.30%-- 
CGCCanopy Growth Corp1.37-0.02-1.44%-- 
VTRSViatris9.96-0.21-2.06%227.2PE
TEVATeva Pharmaceutical Industries Limited19.93+0.04+0.20%-- 
Quotes are at least 15-min delayed：2025/09/14 07:43 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolioof several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.